Clinical Trials

  • Principal Investigator:

    Uma M. Reddy, MD, MPH
    This research study is being done to is to understand how CPAP for sleep apnea may affect hypertensive disorders of pregnancy and other complications of pregnancy such as gestational diabetes. The purpose of the home sleep test is to find women with sleep apnea. Sleep apnea is when you have one or more pauses in breathing or shallow breaths while you sleep. Studies have shown that women with sleep apnea have an increased risk of high blood pressure and diabetes during pregnancy. If the test shows that you have sleep apnea in the mild to moderate range you will be eligible for a research study...
  • Principal Investigator:

    June Y. Hou, MD
    The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian cancer. The Sponsor continues to study rucaparib in several types of cancers, by itself as well as in combination with other drugs. Rucaparib belongs to a class of anti-cancer agents known as PARP inhibitors. PARP is a protein inside cells that...
  • Principal Investigator:

    Catherine Monk, PHD
    We are working to address the racial disparities in birth outcomes, a pressing issue in women's health research. In particular, we want to better understand the role that mood, stress, and inflammation play in the development of your baby. In our study, participants are asked to engage in up to 3 in-person prenatal sessions at Columbia University Medical Center (168th Street). These sessions are expected to take up to 4.5 hours total. You will have blood drawn and provide hair and saliva samples. At the third trimester session, participants will play a word and color matching game while we...
  • Principal Investigator:

    Carolyn L. Westhoff, MD
    If you are a woman between the ages of 18 and 35, are pre-menopausal, sexually active and do NOT wish to become pregnant, you are invited to see if you may qualify for a research study. The purpose of this research study is to test the effectiveness of an investigational oral birth control pill. If you qualify, you will receive investigational study medication, study-related medical exams, and laboratory services at no charge. You may also be reimbursed for time, travel, and other expenses.
  • Principal Investigator:

    Paula M. Castano, MD, MPH
    Nexplanon a contraceptive implant is currently approved for use up to 3 years. This study is looking to evaluate the contraceptive efficacy of Nexplanon during extended use for 2 more years (5 years total). You may be eligible if you are between the ages of 18-35 and are approaching 36 months from placement of your Nexplanon implant. Study participation would last 3 years and would require the completion of 11 study visits. Compensation for time and travel will be available upon completion of each study visit.
  • Principal Investigator:

    Paula M. Castano, MD, MPH
    Nexplanon a contraceptive implant is currently approved for use up to 3 years. This study is looking to evaluate the contraceptive efficacy of Nexplanon during extended use for 2 more years (5 years total). You may be eligible if you are between the ages of 18-35 and are approaching 36 months from placement of your Nexplanon implant. Study participation would last 3 years and would require the completion of 11 study visits. Compensation for time and travel will be available upon completion of each study visit.
  • Principal Investigator:

    June Y. Hou, MD
    This research study has two parts. Participants will be enrolled in the second part of the study. The names of the study drugs are RGX-104, nivolumab, ipilimumab, docetaxel, carboplatin, and pemetrexed. The purpose of the first part of the study is to determine the highest dose of RGX-104 the body can handle. The purpose of the second part is to determine if the highest dose of RGX-104 determined in the first part might be an effective treatment option for people with advanced cancers. Both parts of the study will try to understand the safety and side effects of RGX-104.
  • Principal Investigator:

    Jason D. Wright, MD
    We are doing this study because we want to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs is better or worse than the usual approach for your endometrial cancer. The usual approach is defined as care most people get for endometrial cancer.
  • Principal Investigator:

    Catherine Monk, PHD
    Do you ever wish there was more information on how to handle the challenges of pregnancy and having a new baby? This study looks into whether certain behavioral techniques used by mothers can help their babies sleep more and cry less and, in turn, improve womens moods and child outcomes. The study starts when you are in your third trimester of pregnancy and lasts until your baby is about 4 months old. After you attend a virtual screening session by phone or video to determine that you are fully eligible for the study, you will have 4 virtual sessions by phone or video; 1) at 28-32 weeks of...
  • Principal Investigator:

    Catherine Monk, PHD
    Do you ever wish there was more information on how to handle the challenges of pregnancy and having a new baby? This study looks into whether certain behavioral techniques used by mothers can help their babies sleep more and cry less and, in turn, improve womens moods and child outcomes. The study starts when you are in your third trimester of pregnancy and lasts until your baby is about 4 months old. After you attend a virtual screening session by phone or video to determine that you are fully eligible for the study, you will have 4 virtual sessions by phone or video; 1) at 28-32 weeks of...

Pages